Suppr超能文献

胰肾联合移植中无类固醇维持免疫抑制的经验。

Experience with steroid-free maintenance immunosuppression in simultaneous pancreas-kidney transplantation.

作者信息

Freise C E, Kang S M, Feng S, Posselt A, Hirose K, Hirose R, Stock P

机构信息

Transplant Division, Department of Surgery, University of California, San Francisco, 94143, USA.

出版信息

Transplant Proc. 2004 May;36(4):1067-8. doi: 10.1016/j.transproceed.2004.04.017.

Abstract

INTRODUCTION

Steroid avoidance is possible in simultaneous pancreas-kidney transplantation with the use of newer immunosuppressive agents and induction therapy. We undertook a retrospective consecutive case review of patients treated at a university tertiary referral center.

METHODS

Medical records of 44 consecutive patients receiving a pancreas-kidney transplant from November 2000 to September 2002 were reviewed. The immunosuppression protocol used in this series of patients consisted of thymoglobulin induction, combined with mycophenolate mofetil, tacrolimus, and sirolimus for maintenance immunosuppression. Steroids were used only while thymoglobulin was given and were typically discontinued by postoperative week 1. Main outcome measures included graft and patient survival rates, rejection rates of the kidney or pancreas, infection rates, and surgical complication rates.

RESULTS

All 44 patients received a kidney-pancreas transplant with systemic venous anastomosis and enteric drainage of the pancreas. Patient kidney, and pancreas survival rates were 95.6%, 93.2%, and 88.7%, respectively. Biopsy-proven pancreas rejection rates at 1 and 6 months posttransplant were 2.3% and 2.3%. Kidney rejection rates at 1 and 6 months were 2.3% and 4.6%. Reasons for patient loss included one death from sepsis and one cardiovascular death. Reasons for kidney loss besides death included a thrombotic microangiopathy. Reasons for pancreas loss included three thromboses, one mild rejection/infection, and one duodenal segment leak with infection. All patients who have been free of rejection have been off steroids for the duration of follow-up.

CONCLUSIONS

Newer immunosuppression protocols without maintenance steroids are possible with minimal rejection in the first 3 months and equivalent patient and graft survival rates compared with earlier protocols utilizing steroids. The potential beneficial long-term impact of steroid avoidance will require further study.

摘要

引言

通过使用新型免疫抑制剂和诱导治疗,在胰肾联合移植中避免使用类固醇是可行的。我们对一家大学三级转诊中心治疗的患者进行了回顾性连续病例分析。

方法

回顾了2000年11月至2002年9月期间连续44例接受胰肾移植患者的病历。本系列患者使用的免疫抑制方案包括用抗胸腺细胞球蛋白诱导,联合霉酚酸酯、他克莫司和西罗莫司进行维持免疫抑制。类固醇仅在给予抗胸腺细胞球蛋白时使用,通常在术后第1周停用。主要观察指标包括移植物和患者生存率、肾脏或胰腺排斥率、感染率和手术并发症发生率。

结果

所有44例患者均接受了胰肾移植,采用全身静脉吻合和胰腺肠内引流。患者的肾脏、胰腺生存率分别为95.6%、93.2%和88.7%。移植后1个月和6个月经活检证实的胰腺排斥率分别为2.3%和2.3%。肾脏在1个月和6个月时的排斥率分别为2.3%和4.6%。患者死亡原因包括1例败血症死亡和1例心血管死亡。除死亡外,肾脏丢失的原因包括血栓性微血管病。胰腺丢失的原因包括3例血栓形成、1例轻度排斥/感染和1例十二指肠段渗漏伴感染。所有未发生排斥反应的患者在随访期间均未使用类固醇。

结论

与早期使用类固醇的方案相比,新型无维持类固醇的免疫抑制方案在前3个月排斥反应最小,患者和移植物生存率相当。避免使用类固醇的潜在长期有益影响需要进一步研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验